Celine Halioua is a visionary at the forefront of biomedical innovation, driving groundbreaking advancements in longevity research. With a background in neuroscience from the University of Texas, Austin, and a deep dive into the economics of gene therapeutics at Oxford University, Halioua has emerged as a trailblazer in the industry. Halioa's work earned her a spot on Forbes' 30 Under 30 - Science list in 2022.

She is the founder and CEO of Loyal, a biotech firm dedicated to pioneering research and developing drugs to extend dog lifespan. Recognizing the potential of identifying compounds to combat aging and cancer in dogs as a pathway to human health, Halioua spearheaded Loyal's mission to develop innovative solutions by leveraging her understanding of regulatory pathways: it is easier to get experimental drugs approved for the veterinarian market than it is for humans. She thereby paved the way for expedited research and development. Under her leadership, Loyal has raised over $38 million in venture capital and initiated clinical trials for their first anti-aging drug. This revolutionary medication targets a cellular mechanism hypothesized to alleviate the mental and physical decline associated with aging.

Prior to Loyal, Halioua pursued a doctorate at Oxford before dropping out in her final year to join the Longevity Fund. At Longevity, she collaborated with industry pioneers before embarking on her own entrepreneurial journey at just 25 years old.

SXSW, Biotechnology, Startup, Pharmaceutical, Neuroscience, Pets, Animals & Wildlife, Aging, Innovation, Health, Cancer, CEO, Chief Executive Officer (CEO), Business Founders, Science,